CochLear Ltd. Unsponsored ADR (OTCMKTS:CHEOY - Get Free Report) hit a new 52-week low during trading on Wednesday . The company traded as low as $33.14 and last traded at $33.17, with a volume of 85315 shares changing hands. The stock had previously closed at $33.93.
Wall Street Analyst Weigh In
A number of equities research analysts have recently commented on CHEOY shares. Zacks Research upgraded shares of CochLear to a "hold" rating in a research report on Friday, April 17th. Royal Bank Of Canada upgraded shares of CochLear from a "hold" rating to a "moderate buy" rating in a research report on Monday, January 19th. Finally, UBS Group cut shares of CochLear from a "strong-buy" rating to a "hold" rating in a research report on Thursday, April 23rd. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, CochLear has an average rating of "Moderate Buy".
View Our Latest Stock Analysis on CHEOY
CochLear Price Performance
The stock's 50-day moving average price is $59.95 and its 200 day moving average price is $79.31.
About CochLear
(
Get Free Report)
Cochlear Limited provides implantable hearing solutions for children and adults worldwide. It offers cochlear implant systems, sound processor upgrades, bone conduction systems, accessories, and other products. Cochlear Limited was founded in 1981 and is headquartered in Sydney, Australia.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider CochLear, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CochLear wasn't on the list.
While CochLear currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.